Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
30 Januar 2008 - 2:00PM
PR Newswire (US)
LAVAL, QC, Jan. 30 /PRNewswire-FirstCall/ -- Neurochem Inc.
(NASDAQ: NRMX; TSX: NRM) is pleased to announce that Mr. Gary
Schmid will join Neurochem, effective February 4, 2008, and will
serve as Chief Executive Officer (CEO) of the new business
Neurochem has announced it is creating to develop and market
nutraceuticals. Mr. Schmid joins the Company from Sante Naturelle
A.G. Limited, the international manufacturers and marketers of
Quebec's market-leading Adrien Gagnon natural health brands. Mr.
Schmid joined Sante Naturelle in May 2006 as Chief Operating
Officer and was appointed President and CEO later that year. In
addition, Mr. Schmid spent 20 years at Abbott Laboratories Ltd. in
a variety of positions of ever-increasing responsibility in sales
and marketing where, in 2005, he was appointed General Manager,
Abbott Nutrition. "We are excited to welcome Mr. Schmid who will
lead the team responsible for the commercialization of our first
nutraceutical product, homotaurine, developed to enhance memory and
cognition. The launch of homotaurine is planned in Canada in the
near future, with subsequent commercial activities in other
territories expected soon thereafter," said Dr. Francesco Bellini,
Chairman, President and Chief Executive Officer of Neurochem. "Mr.
Schmid's long track record and world-class marketing credentials
will help create a unique, branded nutraceutical product company,"
he concluded. As President and CEO of Sante Naturelle A.G., Mr.
Schmid succeeded in developing and implementing that company's
strategies to support future growth expectations, which translated
into significantly increasing sales in domestic and export business
segments and in the launch of 35 new products within 12 months.
Before joining Sante Naturelle, Mr. Schmid held positions with
Abbott Laboratories Ltd. (Canada), where he served between 1985 and
2006, initially as a financial analyst with what was to become
Abbott's nutrition division, and then rapidly moved into sales and
marketing. Following a two-year assignment with Abbott
International Ltd. in Chicago, Mr. Schmid returned to Canada in
1994 as National Sales Manager of the future nutrition division,
progressed to a series of more responsible positions in marketing,
including Marketing Director of Abbott's Pharma Division, before
being appointed General Manager, Abbott Nutrition, in 2005. Mr.
Schmid is a Commerce graduate of McGill University. About Neurochem
Neurochem Inc. is a global health company focused on the research,
development and commercialization of products to provide innovative
health solutions to patients suffering from serious diseases. To
Contact Neurochem For additional information on Neurochem and its
drug development programs, please call the North American toll-free
number 1-877-680-4500 or visit our Web Site at
http://www.neurochem.com/. For Further Information, please contact:
Lise Hebert, PhD (450) 680-4572 Vice President, Corporate
Communications Certain statements contained in this news release,
other than statements of fact that are independently verifiable at
the date hereof, may constitute forward-looking statements. Such
statements, based as they are on the current expectations of
management, inherently involve numerous risks and uncertainties,
known and unknown, many of which are beyond Neurochem Inc.'s
control. Such risks include but are not limited to: the impact of
general economic conditions, general conditions in the
pharmaceutical and/or nutraceutical industry, changes in the
regulatory environment in the jurisdictions in which the Neurochem
group does business, stock market volatility, fluctuations in
costs, and changes to the competitive environment due to
consolidation, that actual results may vary once the final and
quality-controlled verification of data and analyses has been
completed, as well as other risks disclosed in public filings of
Neurochem Inc. Consequently, actual future results may differ
materially from the anticipated results expressed in the
forward-looking statements. The reader should not place undue
reliance, if any, on any forward-looking statements included in
this news release. These statements speak only as of the date made
and Neurochem Inc. is under no obligation and disavows any
intention to update or revise such statements as a result of any
event, circumstances or otherwise. Please see the Annual
Information Form of Neurochem Inc. for further risk factors that
might affect the Neurochem group and its business. DATASOURCE:
NEUROCHEM INC. CONTACT: Lise Hebert, PhD, Vice President, Corporate
Communications, (450) 680-4572,
Copyright